Rekha Hemrajani MBA

Rekha Hemrajani has been our Chief Executive Officer since our inception in August 2020 and serves on our Board of Directors. Ms. Hemrajani is an experienced strategic leader helping biotech companies with corporate strategy and corporate finance, as well as building product pipelines through corporate development. She has extensive senior management experience within the public and private biopharmaceutical companies, and bulge bracket investment banks. Ms. Hemrajani recently served as President & Chief Executive Officer of Aravive, Inc. Ms. Hemrajani previously served as Chief Financial Officer & Chief Operating Officer of Arcus Biosciences, leading finance, investor relations, corporate communications, business and corporate development, strategic planning, and human resources. Prior to Arcus, Ms. Hemrajani served as Chief Operating Officer of RAPT Therapeutics, Chief Financial Officer of Sagimet Biosciences, VP – Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen), and VP of Business Development at Exelixis. Prior to Exelixis, Ms. Hemrajani was VP, of Healthcare Investment Banking at Lehman Brothers and worked at Credit Suisse First Boston as well. Ms. Hemrajani is currently on the Board of ALX Oncology, MaxCyte, and BioAge Labs, Inc.